At Cycle Pharmaceuticals, I served as the sole physician directing US medical affairs across immunology, rare metabolic disease, neurology and hematology. I also ran medical affairs launch activities for two chronic myeloid leukemia products.
I took on Medical Monitor responsibilities for interventional Phase 2, Phase 3 and expanded access studies, assessing adverse events and serious adverse events and reviewing protocols and study documents. I led sponsored Phase IV studies from study design through data analysis and wrote manuscripts based on the work.
At Queen Elizabeth Hospital, King's Lynn, I managed patients across emergency, inpatient and community settings and ran a quality improvement project on inpatient insulin prescribing errors. Earlier clinical experience included medical practice in Italy and clinical research and peer education at Sapienza University.
As an independent biopharmaceutical business consultant, I delivered projects for clients including Genentech and Roche. I built the business case for a Medical Affairs DataMart, supported post-merger systems work, and managed projects including an electronic quality management system deployment.

